C.R. Bard, Inc. (BCR) Stake Maintained by Associated Banc Corp
Associated Banc Corp held its position in shares of C.R. Bard, Inc. (NYSE:BCR) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 839 shares of the medical instruments supplier’s stock at the close of the 2nd quarter. Associated Banc Corp’s holdings in C.R. Bard were worth $265,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in shares of C.R. Bard by 70.4% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after purchasing an additional 190 shares in the last quarter. ClariVest Asset Management LLC bought a new stake in shares of C.R. Bard in the 1st quarter valued at about $148,000. SRS Capital Advisors Inc. raised its holdings in shares of C.R. Bard by 0.7% in the 1st quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after purchasing an additional 4 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of C.R. Bard by 283.8% in the 1st quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock valued at $153,000 after purchasing an additional 369 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. raised its holdings in shares of C.R. Bard by 16.7% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 788 shares of the medical instruments supplier’s stock valued at $196,000 after purchasing an additional 113 shares in the last quarter. Institutional investors and hedge funds own 79.34% of the company’s stock.
Several equities research analysts have recently commented on the stock. Jefferies Group LLC restated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a report on Thursday. BidaskClub lowered shares of C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a report on Tuesday, June 20th. Finally, BMO Capital Markets restated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. C.R. Bard currently has an average rating of “Hold” and an average price target of $285.67.
In related news, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total value of $7,549,757.51. Following the transaction, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.80% of the company’s stock.
C.R. Bard, Inc. (NYSE BCR) opened at 320.49 on Friday. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $324.58. The stock has a market cap of $23.29 billion, a P/E ratio of 42.08 and a beta of 0.60. The stock has a 50 day moving average of $320.21 and a 200-day moving average of $296.89.
C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.08. The company had revenue of $979.70 million for the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $2.54 earnings per share. On average, equities analysts forecast that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.
WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/15/c-r-bard-inc-bcr-stake-maintained-by-associated-banc-corp.html.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.